Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anatibant
- Development stage
- Unknown
- Lead developer
- Xytis
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Anatibant is a potent and selective small-molecule antagonist of the bradykinin B2 receptor. It was developed for the treatment of traumatic brain injury (TBI). Anatibant is a non-peptide compound that crosses the blood-brain barrier and has been shown in preclinical models to reduce brain edema formation, intracranial hypertension, and histopathological damage following experimental TBI. Its mechanism of action involves inhibiting bradykinin from binding to the B2 receptor, thereby reducing vascular permeability and subsequent post-traumatic brain edema. Clinical development reached Phase 2 trials but was discontinued. The drug was originally developed by Xytis and Fournier[1][3][4][5][7].
- Other names
- anatibant mesilate
02
Targets
Bradykinin B2 receptor
Beyond the preview
Go deeper on anatibant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anatibant.